Review
Year 2018,
Volume: 6 Issue: 4, 5 - 9, 02.04.2018
Abstract
Abstract
Imagine that you are in a medical competition... They give two clues to the competitors and want them to find the right diagnosis. These are the clues givento you. The first diagnosis that comes out of your mind is diabetic neuropathy,right? Why do we consider the first diabetic neuropathy, when there are many diseases and conditions that can cause neuropathy and these findings? In this review, I tried to summarize the definition, epidemiology, diagnosis, treatment and follow-up of diabetic neuropathy with the answer to this question.
Keywords
References
- Kaynaklar 1. Vas PRJ, Edmonds ME. Early recognition of diabeticperipheral neuropathy and the need for one-stop mic-rovascular assessment.Lancet Diabetes Endocrinol. 2016Sep;4(9):723-725. 2. Dimova R, Tankova T, Guergueltcheva V, Tournev I,Chakarova N, Grozeva G, et al. Risk factors for auto-nomic and somatic nerve dysfunction in different sta-ges of glucose tolerance. J Diabetes Complications. 2017Mar;31(3):537-543. 3. Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiologyof polyneuropathy in diabetes and prediabetes. Handb ClinNeurol. 2014;126:3-22. 4. Papanas N, Ziegler D. Risk Factors and Comorbiditi-es in Diabetic Neuropathy: An Update 2015. Rev Dia-bet Stud. 2015 Spring-Summer;12(1-2):48-62. 5. Shaw JE, Hodge AM, de Courten M, Dowse GK, Ga-reeboo H, Tuomilehto J, et al. Diabetic neuropathy inMauritius: prevalence and risk factors. Diabetes Res ClinPract. 1998 Nov;42(2):131-9. 6. Morrison S, Colberg SR, Parson HK, Vinik AI. Relati-on between risk of falling and postural sway complexityin diabetes. Gait Posture. 2012 Apr;35(4):662-8. 7. Boulton AJ. The pathway to foot ulceration in diabetes.Med Clin North Am. 2013 Sep;97(5):775-90. 8. Perkins BA, Olaleye D, Zinman B, Bril V. Simple scree-ning tests for peripheral neuropathy in the diabetes cli-nic. Diabetes Care. 2001 Feb;24(2):250-6. 9. Callaghan BC, Kerber KA, Lisabeth LL, MorgensternLB, Longoria R, Rodgers A, et al. Role of neurologistsand diagnostic tests on the management of distalsymmetric polyneuropathy. JAMA Neurol. 2014 Sep;71(9):1143- 10. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Ca-nal N, Greene DA. A practical two-step quantitative cli-nical and electrophysiological assessment for the diag-nosis and staging of diabetic neuropathy. Diabetes Care.1994 Nov;17(11):1281-9. 11. Diabetes Control and Complications Trial Research Gro-up, Nathan DM, Genuth S, Lachin J, Cleary P, CroffordO, Davis M, et al. The effect of intensive treatment ofdiabetes on the development and progression of long-term complications in insulin-dependent diabetes mel-litus. N Engl J Med. 1993 Sep 30;329(14):977-86. 12. UK Prospective Diabetes Study (UKPDS) Group. Inten-sive blood-glucose control with sulphonylureas or in-sulin compared with conventional treatment and risk ofcomplications in patients with type 2 diabetes (UKPDS33). Lancet. 1998 Sep 12;352(9131):837-53. 13. Diabetes Control and Complications Trial Research Gro-up. Effect of intensive diabetes treatment on nerve con-duction in the Diabetes Control and Complications Tri-al. Ann Neurol. 1995 Dec;38(6):869-80. 14. Callaghan BC, Little AA, Feldman EL, Hughes RA. En-hanced glucose control for preventing and treating dia-betic neuropathy. Cochrane Database Syst Rev. 2012Jun 13;(6):CD007543. doi: 10.1002/14651858. 15. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, FreemanR, Malik RA, et al. Diabetic Neuropathy: A Position Sta-tement by the American Diabetes Association.DiabetesCare. 2017 Jan;40(1):136-154. 16. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dub-ner R. Effects of desipramine, amitriptyline, and fluo-xetine on pain in diabetic neuropathy. N Engl J Med.1992 May 7;326(19):1250-6. 17. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for trea-ting painful neuropathy or chronic pain. Cochrane Da-tabase Syst Rev. 2009 Oct 7;(4):CD007115. 18. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxineextended release in the treatment of painful diabetic neu-ropathy: a double-blind, placebo-controlled study.Pain. 2004 Aug;110(3):697-706. 19. Backonja MM. Use of anticonvulsants for treatment ofneuropathic pain. Neurology. 2002 Sep 10;59(5 Suppl2):S14-7. 20. Ametov AS, Barinov A, Dyck PJ, Hermann R, KozlovaN, Litchy WJ, et al; SYDNEY Trial Study Group. Thesensory symptoms of diabetic polyneuropathy are im-proved with alpha-lipoic acid: the SYDNEY trial. Dia-betes Care. 2003 Mar;26(3):770-6. 21. Bril V, England JD, Franklin GM, Backonja M, CohenJ, Del Toro D, et al; American Academy of Neurology;American Association of Neuromuscular and Electrodi-agnostic Medicine; American Academy of Physical Me-dicine and Rehabilitation. Evidence-based guideline: Tre-atment of painful diabetic neuropathy: report of the Ame-rican Academy of Neurology, the American Associationof Neuromuscular and Electrodiagnostic Medicine, andthe American Academy of Physical Medicine and Reha-bilitation. Muscle Nerve. 2011 Jun;43(6):910-7.
Year 2018,
Volume: 6 Issue: 4, 5 - 9, 02.04.2018
Abstract
Öz
Bir tıp yarışmasında olduğunuzu hayal edin… Yarışmacılara iki adet ipucu veriliyor ve doğru tanıyı koymaları isteniyor. Size verilen ipuçları bunlar. Çoğumuzun aklına gelen ilk tanı diyabetik nöropati oluyor değil mi? Nöropati ve bu bulguları yapabilecek birçok hastalık ve durum varken neden ilk diyabetik nöropatiyi düşünüyoruz? Bu derlemede bu sorunun cevabı ile birlikte diyabetik nöropatinin tanımı, epidemiyolojisi, tanısı, tedavisi ve izlemi konularını özetlemeyeçalıştım.
Keywords
References
- Kaynaklar 1. Vas PRJ, Edmonds ME. Early recognition of diabeticperipheral neuropathy and the need for one-stop mic-rovascular assessment.Lancet Diabetes Endocrinol. 2016Sep;4(9):723-725. 2. Dimova R, Tankova T, Guergueltcheva V, Tournev I,Chakarova N, Grozeva G, et al. Risk factors for auto-nomic and somatic nerve dysfunction in different sta-ges of glucose tolerance. J Diabetes Complications. 2017Mar;31(3):537-543. 3. Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiologyof polyneuropathy in diabetes and prediabetes. Handb ClinNeurol. 2014;126:3-22. 4. Papanas N, Ziegler D. Risk Factors and Comorbiditi-es in Diabetic Neuropathy: An Update 2015. Rev Dia-bet Stud. 2015 Spring-Summer;12(1-2):48-62. 5. Shaw JE, Hodge AM, de Courten M, Dowse GK, Ga-reeboo H, Tuomilehto J, et al. Diabetic neuropathy inMauritius: prevalence and risk factors. Diabetes Res ClinPract. 1998 Nov;42(2):131-9. 6. Morrison S, Colberg SR, Parson HK, Vinik AI. Relati-on between risk of falling and postural sway complexityin diabetes. Gait Posture. 2012 Apr;35(4):662-8. 7. Boulton AJ. The pathway to foot ulceration in diabetes.Med Clin North Am. 2013 Sep;97(5):775-90. 8. Perkins BA, Olaleye D, Zinman B, Bril V. Simple scree-ning tests for peripheral neuropathy in the diabetes cli-nic. Diabetes Care. 2001 Feb;24(2):250-6. 9. Callaghan BC, Kerber KA, Lisabeth LL, MorgensternLB, Longoria R, Rodgers A, et al. Role of neurologistsand diagnostic tests on the management of distalsymmetric polyneuropathy. JAMA Neurol. 2014 Sep;71(9):1143- 10. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Ca-nal N, Greene DA. A practical two-step quantitative cli-nical and electrophysiological assessment for the diag-nosis and staging of diabetic neuropathy. Diabetes Care.1994 Nov;17(11):1281-9. 11. Diabetes Control and Complications Trial Research Gro-up, Nathan DM, Genuth S, Lachin J, Cleary P, CroffordO, Davis M, et al. The effect of intensive treatment ofdiabetes on the development and progression of long-term complications in insulin-dependent diabetes mel-litus. N Engl J Med. 1993 Sep 30;329(14):977-86. 12. UK Prospective Diabetes Study (UKPDS) Group. Inten-sive blood-glucose control with sulphonylureas or in-sulin compared with conventional treatment and risk ofcomplications in patients with type 2 diabetes (UKPDS33). Lancet. 1998 Sep 12;352(9131):837-53. 13. Diabetes Control and Complications Trial Research Gro-up. Effect of intensive diabetes treatment on nerve con-duction in the Diabetes Control and Complications Tri-al. Ann Neurol. 1995 Dec;38(6):869-80. 14. Callaghan BC, Little AA, Feldman EL, Hughes RA. En-hanced glucose control for preventing and treating dia-betic neuropathy. Cochrane Database Syst Rev. 2012Jun 13;(6):CD007543. doi: 10.1002/14651858. 15. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, FreemanR, Malik RA, et al. Diabetic Neuropathy: A Position Sta-tement by the American Diabetes Association.DiabetesCare. 2017 Jan;40(1):136-154. 16. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dub-ner R. Effects of desipramine, amitriptyline, and fluo-xetine on pain in diabetic neuropathy. N Engl J Med.1992 May 7;326(19):1250-6. 17. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for trea-ting painful neuropathy or chronic pain. Cochrane Da-tabase Syst Rev. 2009 Oct 7;(4):CD007115. 18. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxineextended release in the treatment of painful diabetic neu-ropathy: a double-blind, placebo-controlled study.Pain. 2004 Aug;110(3):697-706. 19. Backonja MM. Use of anticonvulsants for treatment ofneuropathic pain. Neurology. 2002 Sep 10;59(5 Suppl2):S14-7. 20. Ametov AS, Barinov A, Dyck PJ, Hermann R, KozlovaN, Litchy WJ, et al; SYDNEY Trial Study Group. Thesensory symptoms of diabetic polyneuropathy are im-proved with alpha-lipoic acid: the SYDNEY trial. Dia-betes Care. 2003 Mar;26(3):770-6. 21. Bril V, England JD, Franklin GM, Backonja M, CohenJ, Del Toro D, et al; American Academy of Neurology;American Association of Neuromuscular and Electrodi-agnostic Medicine; American Academy of Physical Me-dicine and Rehabilitation. Evidence-based guideline: Tre-atment of painful diabetic neuropathy: report of the Ame-rican Academy of Neurology, the American Associationof Neuromuscular and Electrodiagnostic Medicine, andthe American Academy of Physical Medicine and Reha-bilitation. Muscle Nerve. 2011 Jun;43(6):910-7.
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Makaleler 1 |
| Authors | |
| Publication Date | April 2, 2018 |
| Published in Issue | Year 2018 Volume: 6 Issue: 4 |
